Asit Parikh

Asit Parikh is a physician-scientist turned biotech chief executive who runs MOMA Therapeutics, a Cambridge, Massachusetts company built around the idea of systematically drugging molecular machines - the highly dynamic, shape-shifting proteins that most drug hunters avoid. An MD-PhD trained at Vanderbilt with clinical roots in gastroenterology, he spent two decades at Millennium and Takeda, where he helped steer the inflammatory bowel disease drug vedolizumab (Entyvio) from research to global blockbuster, before taking the CEO seat at MOMA in 2021. He has since raised a $150 million Series B and signed a roughly $2 billion partnership with Roche to push precision cancer medicines toward the clinic.